New York, January 8, 2026, 14:02 EST — Regular session
Teleflex Incorporated shares slid 11.7% to $111.76 by mid-afternoon on Thursday after the medical device maker disclosed a CEO exit and trimmed its revenue forecast. The company said it was “the right time to transition leadership” as it pushes through a portfolio shift. Teleflex Investors
The drop matters because Teleflex is in the middle of a reset it has sold to investors as a cleanup job: slim down the company and lean harder into critical-care products. In December, Teleflex agreed to sell three businesses for $2.03 billion to sharpen its focus, with the deals expected to close in the second half of 2026.
On sales, Teleflex now expects full-year 2025 revenue of $3.270 billion to $3.278 billion, down from prior guidance of $3.305 billion to $3.320 billion. The company blamed softer-than-expected demand for intra-aortic balloon pumps and catheters in the U.S. and Asia at year-end, plus delays in purchase orders in its OEM business, which makes products for other companies. Teleflex said the figures are preliminary, with the quarter-end close still under way, and it expects to report full fourth-quarter and full-year results in late February or early March.
The leadership change was immediate. Liam Kelly left as president and chief executive at the end of Wednesday, and director Stuart Randle was appointed interim CEO on Thursday, an SEC filing showed. The board hired Spencer Stuart to run the search for a permanent CEO; the filing also said Randle will receive a $140,000-a-month stipend and a restricted stock grant valued at $1.5 million, due to be granted on January 13.
The move snapped a run higher in the stock. Teleflex ended Wednesday at $126.53 after five straight sessions of gains, and it remains well below its 52-week high of $185.94 set on Jan. 27, 2025, MarketWatch data showed.
Elsewhere in medtech, the tape was calmer. Johnson & Johnson was down about 1%, Medtronic eased roughly 0.2%, while Boston Scientific traded up about 1.1%.
What could go wrong from here is fairly plain: if the year-end slowdown in balloon-pump demand stretches into the new quarter, or if delayed orders slip again, investors may start to treat Thursday’s revenue cut as a trend, not a bump. The CEO search adds another moving part; “interim” can drag on.
